Huifeng starts up new production facility

Huifeng Bio-Pharmaceutical Technology, of Xi'an, China, a leader in the development and production of plant extracts, pharmaceuticals and pharmaceutical raw materials in mainland China and internationally, has started up anew production facility.

The new Xi'an facility will be processing an initial 1.5 tons of L-Rhamnose with a value of about $100,000 to be exported to the KFM Company in Germany. L-Rhamnose, fermented and extracted from waste materials of quercetin, is an additive used in a variety of health foods. Other Huifeng products include troxerutin, quercetin, Ginko Biloba and diosmin, manufactured for use as the building blocks of drugs, dietary supplements and as additives in functional foods and beverages.

'This represents a major expansion of the manufacturing capacity for Huifeng,' said Jing An Wang, founder and ceo of Bio-Pharmaceutical Technology, Inc. 'We believe that this demonstrates our ability to access foreign markets with our quality products.'

US drug and nutraceutical manufacturers' demand for rutin, quercertin and troxeruin is expected to grow by approximately 15% in the next four years, according to industry projections.

Huifeng Bio-Pharmaceutical Technology, Inc. located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived flavonoids, with medicinal and other beneficial properties.

Founded in 2000, Huifeng uses proprietary patented processes to extract Rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organisations.